Aasander Frostner 2022 Abstract Bioblast: Difference between revisions
No edit summary |
No edit summary |
||
Line 25: | Line 25: | ||
::::# Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden | ::::# Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden | ||
== | == List of abbreviations, terms and definitions - MitoPedia == | ||
Β | {{Template:List of abbreviations, terms and definitions - MitoPedia}} | ||
{{Labeling | {{Labeling |
Revision as of 12:24, 28 May 2022
Γ
sander Frostner Eleonor, SimΓ³n Serrano S, Chamkha I, Donnelly E, ElmΓ©r E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. Bioblast 2022: BEC Inaugural Conference. Β»MitoFit PreprintΒ« |
Link: Bioblast 2022: BEC Inaugural Conference
Aasander Frostner Eleonor, Simon Serrano Sonia, Chamkha Imen, Donnelly Ellen, Elmer Eskil, Hansson Magnus J (2022)
Event: Bioblast 2022
Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders affecting approximately 125 persons per million. Mutations underlying these diseases give rise to biological changes (including decrease in energy production and increase in reactive oxygen species), leading to organ failure, and commonly early morbidity. Mitochondrial diseases often present in early childhood and lead to the development of severe symptoms, with severe fatigue and myopathy being some of the most prevalent and debilitating ones.
There is currently no cure for primary mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders.
Present drug development in mitochondrial diseases focuses mainly on modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, and energy replacement.
In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsor.
β’ Keywords: mitochondrial disease, clinical development, mechanism of action, small molecules, industrial sponsors
β’ O2k-Network Lab: SE Lund Elmer E
Affiliations
- Γ sander Frostner E1,2, SimΓ³n Serrano S1,2, Chamkha I1,2, Donnelly E1, ElmΓ©r E1,2, Hansson MJ1,2
- Abliva AB, Medicon Village, 223 81 Lund, Sweden
- Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
List of abbreviations, terms and definitions - MitoPedia
Labels: MiParea: mt-Medicine, Pharmacology;toxicology
Pathology: Inherited
Stress:Mitochondrial disease
Organism: Human